The HIVE community supports Canadian dermatologists, allergists, immunologists and others with an interest in urticaria

Home
About HIVE
The Buzz
Whiteboard
Contact

Protected: Dr. Vipul Jain reviews study “Ligelizumab achieves fast control of symptoms in more patients with chronic spontaneous urticaria versus omalizumab” as presented at the 2020 European Academy of Dermatology and Venereology Conference [Video 21 min]

February 12, 2021 ~ hivecanada

This content is password protected. To view it please enter your password below:

Password:

‹ PreviousDr. Anne Ellis reviews the Ligelizumab Phase 2b core study in CSU [Video 9 min]

Next ›Introducing “The Buzz”, a monthly feature of the HIVE community where recent articles are selected and summarized for clinical relevance to Canadian allergists, immunologists and dermatologists

Not a HIVE member?
Sign up here

The Health Innovation Virtual Engagement (HIVE) is a cross-specialty learning community for Canadian physicians, to support collaboration and enhance understanding of the condition of urticaria.

Some content on this site is password protected, available to HIVE members. You can find the password in your weekly Sosido HIVE email digest, sent every Wednesday.

Search for:

Website Powered by WordPress.com.

Follow Following
- The HIVE Community
- Already have a WordPress.com account? Log in now.

Related